RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.21.20159178
DO 10.1101/2020.07.21.20159178
A1 Wu, Jun
A1 Liang, Boyun
A1 Chen, Cunrong
A1 Wang, Hua
A1 Fang, Yaohui
A1 Shen, Shu
A1 Yang, Xiaoli
A1 Wang, Baoju
A1 Chen, Liangkai
A1 Chen, Qi
A1 Wu, Yang
A1 Liu, Jia
A1 Yang, Xuecheng
A1 Li, Wei
A1 Zhu, Bin
A1 Zhou, Wenqing
A1 Wang, Huan
A1 Li, Shumeng
A1 Lu, Sihong
A1 Liu, Di
A1 Li, Huadong
A1 Krawczyk, Adalbert
A1 Lu, Mengji
A1 Yang, Dongliang
A1 Deng, Fei
A1 Dittmer, Ulf
A1 Trilling, Mirko
A1 Zheng, Xin
YR 2020
UL http://medrxiv.org/content/early/2020/07/24/2020.07.21.20159178.abstract
AB Long-term antibody responses and neutralizing activities following SARS-CoV-2 infections have not yet been elucidated. We quantified immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) of the spike (S) or the nucleocapsid (N) protein, and neutralizing antibodies during a period of six months following COVID-19 disease onset in 349 symptomatic COVID-19 patients, which were among the first world-wide being infected. The positivity rate and magnitude of IgM-S and IgG-N responses increased rapidly. High levels of IgM-S/N and IgG-S/N at 2-3 weeks after disease onset were associated with virus control and IgG-S titers correlated closely with the capacity to neutralize SARS-CoV-2. While specific IgM-S/N became undetectable 12 weeks after disease onset in most patients, IgG-S/N titers showed an intermediate contraction phase, but stabilized at relatively high levels over the six months observation period. At late time points the positivity rates for binding and neutralizing SARS-CoV-2-specific antibodies was still over 70%. Taken together, our data indicate sustained humoral immunity in recovered patients who suffer from symptomatic COVID-19, suggesting prolonged immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Science and Technology Major Project for Infectious Diseases of China (2018ZX10302206, 2018ZX10723203, and 2017ZX10304402-002-005);the Fundamental Research Funds for the Central Universities (2020kfyXGYJ016, 2020kfyXGYJ028, and 2020kfyXGYJ046); the Tongji-Rongcheng Center for Biomedicine, Huazhong University of Science and Technology, the Medical Faculty of the University of Duisburg-Essen, and Stiftung Universitatsmedizin Essen, University Hospital Essen, Germany.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Commission of Union Hospital of Huazhong University of Science and Technology in Wuhan.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, and code generated or used during the study appear in the submitted article.COVID-19Corona Virus Disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2SARSsevere acute respiratory syndromeMERSmiddle east respiratory syndromeELISAenzyme-linked Immunosorbent AssayRBDreceptor-binding domainRT-PCRreverse transcription-polymerase chain reactionPaO2/FiO2arterial oxygen tension to inspired oxygen fractionCLIAcapture chemiluminescence immunoassaysVNTvirus neutralization test